沙雷肽酶 Serrapeptase
C 2 D 1
適應症與證據等級
法規與權威立場 (L4)
L4a · US FDA
立場:cautious
Products may be legally marketed as dietary supplements if claims about diagnosis, cure, mitigation, treatment, or prevention are removed from promotional materials and the products otherwise comply with all applicable provisions of the Act and FDA regulations.
來源 ↗ L4b · EU EFSA
立場:against
L4c · UK NHS
立場:against
Serratiopeptidase is an unauthorised novel food, and it is illegal for businesses to sell serrapeptase as a food supplement for human consumption in the EU and UK because it is an unauthorised novel food.
來源 ↗ L4e · WHO
立場:not_addressed
市場與行銷 (L10)
L10a · TW Market Channels
強效沙雷肽酶Serrapeptase(延遲釋放)
L10b · TW Legal Identity (TFDA)
以現在要求的臨床數據評估,並無足夠證據足以支持其療效
L10c · TW Community (PTT/Dcard/Mobile01)